According to a new report, published by KBV research, The Global Cluster Headache Market size is expected to reach $437.5 Million by 2028, rising at a market growth of 4.0% CAGR during the forecast period.
The Hospital Pharmacies segment is showcasing a CAGR of 4.4% during (2022 - 2028). This is due to increased financing from private and public hospital pharmacies for treating cluster headaches. Hospital pharmacies do the selection, prescription, procurement, delivery, administration, and review of pharmaceuticals to improve patient outcomes. In addition, there is an associated rise in awareness of the need for early diagnosis. These are the main factors surging the growth of the segment.
The Episodic segment acquired maximum revenue share in the Global Cluster Headache Market by Type in 2021 thereby, achieving a market value of $300.2 Million by 2028. This is because of the increase in people experiencing episodic attacks. In cases with episodic cluster headaches, the headaches continue for a week to a year, then go away for three months or more before returning. Also, there is an increase in the regulatory approval of medications designed to treat episodic cluster headaches. These factors are expected to boost the segment's expansion.
The Calcium Channel Blockers segment has shown the growth rate of 4.9% during (2022 - 2028). This is due to their effectiveness in preventing CH (Cluster Headache). These can be combined with lithium or ergotamine. Although other calcium channels blockers like nimodipine and diltiazem have also shown promise, verapamil may be the most effective. Lithium has been proposed as a therapy option for CH due to its cyclical nature, similar to bipolar illnesses.
The North America market dominated the Global Cluster Headache Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $162 Million by 2028. The Asia Pacific market is exhibiting a CAGR of 4.8% during (2022 - 2028). Additionally, The Europe market would showcase a CAGR of 3.4% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/cluster-headache-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Dr. Reddy’s Laboratories Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC (GSK), Pfizer, Inc., Fresenius SE & Co. KGaA, Eli Lilly And Company, Grünenthal GmbH, and Arrotex Pharmaceuticals Pty Limited.
By Distribution channel
By Type
By Drug Class
By Geography
Companies Profiled
Unique Offerings 
